Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Fast food is crowding out grocery access across the U.S.

4

Jun 2026

Fast food is crowding out grocery access across the U.S.

A 20-year analysis of US neighborhood foodscapes found that food swamps became more common from 2003 to 2023, while food deserts showed little improvement. Rural communities and people relying on public transport faced the greatest barriers to reaching healthy food retailers.

What older adults eat may shape dementia risk

4

Jun 2026

What older adults eat may shape dementia risk

Higher ultraprocessed food intake was associated with increased risks of dementia, cognitive impairment with no dementia, and the combined outcome among older US adults in the Health and Retirement Study. Minimally processed food intake showed the opposite pattern, although the observational findings require cautious interpretation because diet was self-reported and cognitive outcomes were not clinically diagnosed.

Novel technology maps single-cell DNA-protein interactions

4

Jun 2026

Novel technology maps single-cell DNA-protein interactions

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.